SAS Output

16-OCT-2019 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 23 17 11 3 2 1 SURV
      2 Randomization Non-surgical M 22 16 10 6 3 0  
      3 Patient Choice Surgery 65 15 4 0 0 0  
      4 Patient Choice Non-surgical M 100 0 0 0 0 0  
        210 48 25 9 5 1  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 716 145 29 14 4 1 CCD
      2 Site randomized: Control 631 236 114 56 17 1  
      3 SiteRand Int Risk: CSF 1232 544 286 125 34 4  
      4 SiteRand Int Risk: No CSF 937 385 182 94 34 2  
        3516 1310 611 289 89 8  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 690 362 180 90 30 5 BREAST
        690 362 180 90 30 5  
 
  2 Y 2 Observation 294 154 75 38 11 1  
      3 MK-3475 (Pembrolizumab) 292 152 82 39 12 2  
        586 306 157 77 23 3  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 156 109 55 31 8 1 SURV
        156 109 55 31 8 1  
 
  2 Y 1 Carvedilol 30 22 12 7 2 0  
      2 No prophylaxis 29 22 9 7 2 0  
      3 Observation 90 65 36 18 6 0  
        149 109 57 32 10 0  
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition 1 T 1 Blinded Nutrition Drink 5 5 4 3 1 0 SXQOL
      2 Blinded Nutrition Drink 10 10 8 4 1 0  
        15 15 12 7 2 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 T 1 TICE BCG 168 110 67 21 0 0 GU
      2 Tokyo-172 BCG 168 111 69 23 0 0  
      3 Prime + Tokyo-172 BCG 167 113 68 21 0 0  
        503 334 204 65 0 0  
 
S1614-HBV in Ca Pts, TAF vs SOC 1 Y   0 0 0 0 0 0 SXQOL
        0 0 0 0 0 0  
 
S1703-Met Breast, STM-monitoring v Usual Care 1 Y 0 Screening 81 77 41 19 7 1 CCD
        81 77 41 19 7 1  
 
  2 Y 1 Control (Usual Care) 21 21 17 8 2 0  
      2 Intervention (STMDDM) 20 20 16 6 2 0  
        41 41 33 14 4 0  
 
S1714-CIPN Risk Prediction Cohort Study, Taxanes 1 Y 1 Observation 68 68 68 54 15 3 SXQOL
        68 68 68 54 15 3  
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 119 112 67 44 16 4 GU
        119 112 67 44 16 4  
 
  2 Y 1 Standard Systemic Therapy Only 32 31 21 13 5 1  
      2 SST + Surgery/RT 33 32 23 14 3 1  
        65 63 44 27 8 2  
 
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab 1 Y 0 Initial Registration 14 14 14 11 4 0 GU
        14 14 14 11 4 0  
 
  2 Y 1 Chemo + RT 6 6 6 4 1 0  
      2 Chemo + RT + Atezolizumab 5 5 5 4 1 0  
        11 11 11 8 2 0  
 
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD 1 Y 1 Nivolumab + AVD 6 6 6 6 5 2 LYMPH
      2 Brentuximab Vedotin + AVD 6 6 6 6 4 1  
        12 12 12 12 9 3  
 
S1916-Pain, Mets, Opioid Digital Medicine Pilot 1 Y   0 0 0 0 0 0 CCD
        0 0 0 0 0 0  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 584 82 38 9 5 1 PREV
        584 82 38 9 5 1  
 
  1 Y 1 Blinded drug 93 22 9 1 0 0  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 93 19 14 9 4 1  
        257 41 23 10 4 1  
 

16-OCT-2019 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Open Studies with No Registrations
S1614-HBV in Ca Pts, TAF vs SOC regtype: 1
S1916-Pain, Mets, Opioid Digital Medicine Pilot regtype: 1